Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 8, 2026, 3:06 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 160 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Philadelphia Chromosome Positive Clear all
Completed Phase 1Phase 2 Interventional

Arsenic Trioxide and Imatinib Mesylate in Treating Patients With Accelerated Phase or Blastic Phase Chronic Myelogenous Leukemia or Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia

NCT00081133
View directory record Official record
Conditions
Leukemia
Interventions
arsenic trioxide, imatinib mesylate
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2005
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 4, 2013 · Synced Sep 8, 2026, 3:06 AM EDT
Temporarily Not Available No phase listed Expanded access

Expanded Access to Vodobatinib for Patients With Philadelphia Chromosome-Positive Chronic Myeloid Leukemia Who Have Not Responded to Previous Treatments

NCT07517315
View directory record Official record
Conditions
CML, Relapsed, CML, Refractory
Interventions
K0706
Drug
Lead sponsor
Sun Pharma Advanced Research Company Limited
Industry
Eligibility
18 Years and older
U.S. locations
2
States / cities
Augusta, Georgia • Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Apr 14, 2026 · Synced Sep 8, 2026, 3:06 AM EDT
Terminated Phase 2 Interventional Results available

Imatinib Mesylate Plus Cytarabine in Treating Patients With Chronic Myelogenous Leukemia

NCT00022490
View directory record Official record
Conditions
Leukemia
Interventions
cytarabine, imatinib mesylate
Drug
Lead sponsor
OHSU Knight Cancer Institute
Other
Eligibility
18 Years to 120 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2011
U.S. locations
2
States / cities
Boston, Massachusetts • Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Jan 6, 2016 · Synced Sep 8, 2026, 3:06 AM EDT
Completed Phase 1Phase 2 Interventional

Arsenic Trioxide and Imatinib Mesylate in Treating Patients With Chronic Myelogenous Leukemia

NCT00053248
View directory record Official record
Conditions
Leukemia
Interventions
arsenic trioxide, imatinib mesylate
Drug
Lead sponsor
OHSU Knight Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2005
U.S. locations
3
States / cities
Los Angeles, California • Tampa, Florida • Portland, Oregon
Source: ClinicalTrials.gov public record
Updated May 27, 2012 · Synced Sep 8, 2026, 3:06 AM EDT
Terminated Phase 2 Interventional

Interferon Alfa Plus Sargramostim in Treating Patients With Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia

NCT00003561
View directory record Official record
Conditions
Leukemia
Interventions
recombinant interferon alfa, sargramostim
Biological
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years and older
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2010
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 19, 2011 · Synced Sep 8, 2026, 3:06 AM EDT
Withdrawn Phase 1Phase 2 Interventional

Clinical Trial of BP1001 (Liposomal Grb2 Antisense Oligonucleotide) in Combination With Dasatinib in Patients With Ph + CML Who Have Failed TKI, Ph+ AML, Ph+ MDS

NCT02923986
View directory record Official record
Conditions
Chronic Myelogenous Leukemia, Ph1-Positive, Acute Myeloid Leukemia, Myelodysplastic Syndrome
Interventions
BP1001 (varying dose), BP1001 (fixed dose), Dasatinib
Drug
Lead sponsor
Bio-Path Holdings, Inc.
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 27, 2020 · Synced Sep 8, 2026, 3:06 AM EDT
Completed Phase 1 Interventional

Belinostat and Azacitidine in Treating Patients With Advanced Hematologic Cancers or Other Diseases

NCT00351975
View directory record Official record
Conditions
Accelerated Phase of Disease, Adult Acute Myeloid Leukemia With Inv(16)(p13.1q22); CBFB-MYH11, Adult Acute Myeloid Leukemia With t(16;16)(p13.1;q22); CBFB-MYH11, Adult Acute Myeloid Leukemia With t(8;21)(q22;q22); RUNX1-RUNX1T1, Adult Acute Myeloid Leukemia With t(9;11)(p22;q23); MLLT3-MLL, Adult Acute Promyelocytic Leukemia With t(15;17)(q22;q12); PML-RARA, Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative, Blastic Phase, Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Chronic Myelomonocytic Leukemia, de Novo Myelodysplastic Syndrome, Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable, Philadelphia Chromosome Negative, BCR-ABL1 Positive Chronic Myelogenous Leukemia, Previously Treated Myelodysplastic Syndrome, Primary Myelofibrosis, Recurrent Adult Acute Lymphoblastic Leukemia, Recurrent Adult Acute Myeloid Leukemia, Recurrent Disease, Secondary Acute Myeloid Leukemia, Secondary Myelodysplastic Syndrome
Interventions
Belinostat, Azacitidine, Laboratory Biomarker Analysis
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2013
U.S. locations
2
States / cities
Chicago, Illinois • Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Dec 22, 2014 · Synced Sep 8, 2026, 3:06 AM EDT
Completed Phase 2 Interventional Results available

Early Administration of ATG Followed by Cyclophosphamide, Busulfan and Fludarabine Before a Donor Stem Cell Transplant in Patients With Hematological Cancer

NCT00787761
View directory record Official record
Conditions
Myeloproliferative Disorders, Kidney Cancer, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Diseases
Interventions
anti-thymocyte globulin, busulfan, cyclophosphamide, fludarabine phosphate, methotrexate, tacrolimus, nonmyeloablative allogeneic HSCT
Biological · Drug · Procedure
Lead sponsor
Northside Hospital, Inc.
Other
Eligibility
Up to 75 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Sep 30, 2012 · Synced Sep 8, 2026, 3:06 AM EDT
Completed Phase 2 Interventional Results available

An Extension Study of the Safety and Anti-leukemic Effects of Imatinib Mesylate in Participants With Philadelphia Chromosome-positive Chronic Myeloid Leukemia in Blast Crisis

NCT00171158
View directory record Official record
Conditions
Philadelphia Chromosome Positive CML
Interventions
imatinib mesylate
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
260 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2013
U.S. locations
3
States / cities
Chicago, Illinois • Boston, Massachusetts • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jun 24, 2021 · Synced Sep 8, 2026, 3:06 AM EDT
Completed Phase 2 Interventional Results available

Pegasys® in Patients With Myeloproliferative Diseases

NCT00452023
View directory record Official record
Conditions
Myeloproliferative Disorders
Interventions
IFN-alpha2a
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
83 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2023
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Dec 10, 2024 · Synced Sep 8, 2026, 3:06 AM EDT
Completed Phase 3 Interventional Results available

Advanced Chronic Myelogenous Leukemia (CML) - Follow On: Study of BMS-354825 in Subjects With CML

NCT00123487
View directory record Official record
Conditions
Myeloid Leukemia, Chronic, Accelerated Phase, Leukemia, Lymphoblastic, Acute, Philadelphia-Positive
Interventions
dasatinib
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
638 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2013
U.S. locations
26
States / cities
Birmingham, Alabama • Loma Linda, California • Los Angeles, California + 21 more
Source: ClinicalTrials.gov public record
Updated Nov 2, 2014 · Synced Sep 8, 2026, 3:06 AM EDT
Completed Phase 3 Interventional Results available

A Multicenter Phase 3, Open-Label Study of Bosutinib Versus Imatinib in Adult Patients With Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia

NCT02130557
View directory record Official record
Conditions
Leukemia, Myelogenous, Chronic, Breakpoint Cluster Region-Abelson Proto-oncogene (BCR-ABL) Positive
Interventions
Bosutinib, Imatinib
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
536 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2020
U.S. locations
65
States / cities
Anaheim, California • Atlanta, Georgia • Honolulu, Hawaii + 40 more
Source: ClinicalTrials.gov public record
Updated May 17, 2021 · Synced Sep 8, 2026, 3:06 AM EDT
Active, not recruiting Phase 1 Interventional

Venetoclax, Dasatinib, Prednisone, Rituximab and Blinatumomab for the Treatment of Newly Diagnosed or Relapsed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia or Mixed Phenotype Acute Leukemia

NCT04872790
View directory record Official record
Conditions
B Acute Lymphoblastic Leukemia, B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1, Mixed Phenotype Acute Leukemia, Recurrent B Acute Lymphoblastic Leukemia, Recurrent Mixed Phenotype Acute Leukemia
Interventions
Dasatinib, Methotrexate, Prednisone, Rituximab, Venetoclax, Blinatumomab, Bone Marrow Aspiration and Biopsy, Lumbar Puncture, Biospecimen Collection
Drug · Biological · Procedure
Lead sponsor
OHSU Knight Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated May 5, 2026 · Synced Sep 8, 2026, 3:06 AM EDT
Completed Phase 2 Interventional

Phase II Study of SCH66336, A Farnesyltransferase Inhibitor in Chronic Myelogenous Leukemia (CML)

NCT00038597
View directory record Official record
Conditions
Myelogenous Leukemia, Chronic
Interventions
SCH66336
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
16 Years and older
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2004
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 29, 2018 · Synced Sep 8, 2026, 3:06 AM EDT
Terminated Phase 3 Interventional

Homoharringtonine Compared With Hydroxyurea for Chronic Myelogenous Leukemia That Has Not Responded to Interferon Alfa

NCT00004933
View directory record Official record
Conditions
Leukemia
Interventions
hydroxyurea, Homoharringtonine
Drug
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
16 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2001
U.S. locations
133
States / cities
Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 83 more
Source: ClinicalTrials.gov public record
Updated Jul 3, 2016 · Synced Sep 8, 2026, 3:06 AM EDT
Completed Phase 2 Interventional

Fludarabine and Radiation Therapy in Treating Patients Who Are Undergoing Donor Stem Cell Transplant for Chronic Phase or Accelerated Phase Chronic Myelogenous Leukemia

NCT00110058
View directory record Official record
Conditions
Leukemia
Interventions
recombinant interferon alfa, therapeutic allogeneic lymphocytes, cyclosporine, fludarabine phosphate, imatinib mesylate, mycophenolate mofetil, peripheral blood stem cell transplantation, radiation therapy
Biological · Drug · Procedure + 1 more
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
Not listed
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
3
States / cities
Duarte, California • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Nov 16, 2011 · Synced Sep 8, 2026, 3:06 AM EDT
Terminated Phase 1 Interventional

Ruxolitinib in Treating Participants With Chronic Myeloid Leukemia With Minimal Residual Disease While on Therapy With Tyrosine Kinase Inhibitors

NCT01751425
View directory record Official record
Conditions
Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Chronic Myelogenous Leukemia, BCR-ABL1 Positive in Remission, Minimal Residual Disease, Philadelphia Chromosome Positive, BCR-ABL1 Positive Chronic Myelogenous Leukemia
Interventions
Dasatinib, Imatinib Mesylate, Nilotinib, Ruxolitinib
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2019
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jun 2, 2025 · Synced Sep 8, 2026, 3:06 AM EDT
Active, not recruiting Phase 3 Interventional Results available

A Study of Ponatinib Versus Imatinib in Adults With Acute Lymphoblastic Leukemia

NCT03589326
View directory record Official record
Conditions
Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (Ph+ALL)
Interventions
Ponatinib, Imatinib, Vincristine, Dexamethasone, Cytarabine, Methotrexate, Prednisone
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years and older
Enrollment
245 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2027
U.S. locations
15
States / cities
Birmingham, Alabama • Duarte, California • Los Angeles, California + 11 more
Source: ClinicalTrials.gov public record
Updated Nov 25, 2025 · Synced Sep 8, 2026, 3:06 AM EDT
Recruiting Phase 1 Interventional

ABL001 + Dasatinib + Prednisone + Blinatumomab in BCR-ABL+ B-ALL or CML

NCT03595917
View directory record Official record
Conditions
B-cell Acute Lymphoblastic Leukemia, Chronic Myeloid Leukemia (CML) in Lymphoid Blast Crisis, Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia Ph+ ALL
Interventions
ABL001, Dasatinib, Prednisone, Blinatumomab
Drug
Lead sponsor
Marlise Luskin, MD
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2027
U.S. locations
4
States / cities
Chicago, Illinois • Boston, Massachusetts • Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Nov 3, 2025 · Synced Sep 8, 2026, 3:06 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

Entinostat And Imatinib Mesylate In Treating Patients With Relapsed or Refractory Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia

NCT01383447
View directory record Official record
Conditions
Philadelphia Chromosome Positive Adult Precursor Acute Lymphoblastic Leukemia, Recurrent Adult Acute Lymphoblastic Leukemia
Interventions
entinostat, imatinib mesylate, laboratory biomarker analysis, pharmacological study, western blotting, immunohistochemistry staining method, flow cytometry, polymerase chain reaction, high performance liquid chromatography, mass spectrometry
Drug · Other · Genetic
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 7, 2017 · Synced Sep 8, 2026, 3:06 AM EDT
Terminated Phase 2 Interventional Results available

Intra-patient Dose Escalation Study to Investigate Safety and Feasibility of Vactosertib in Treating Anemic MPN Patients

NCT04103645
View directory record Official record
Conditions
Myeloproliferative Neoplasm
Interventions
Vactosertib
Drug
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 1, 2025 · Synced Sep 8, 2026, 3:06 AM EDT
Recruiting Phase 1 Interventional

A Study of 19-28z/IL-18 in People With Acute Lymphoblastic Leukemia (ALL)

NCT06287528
View directory record Official record
Conditions
Philadelphia-Negative ALL, Philadelphia-Positive ALL, Relapsed ALL, Adult, Refractory Acute Lymphoblastic Leukemia, Refractory Acute Lymphoblastic Leukemia (ALL), Refractory Acute Lymphoid Leukemia in Relapse
Interventions
19-28z/IL-18 CAR T cells
Biological
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
17 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
7
States / cities
Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more
Source: ClinicalTrials.gov public record
Updated Feb 9, 2026 · Synced Sep 8, 2026, 3:06 AM EDT
Not yet recruiting Phase 2 Interventional

Phase II Study of the Combination of Subcutaneous Blinatumomab and Olverembatinib in Patients With Philadelphia Chromosome (ph)-Positive and/or BCR::ABL1 Positive Acute Lymphoblastic Leukemia (ALL)

NCT07178912
View directory record Official record
Conditions
Phase II Clinical Trial, Blinatumomab, Olverembatinib, Lymphoblastic Leukemia, Philadelphia Chromosome Positive
Interventions
Blinatumomab, olverembatinib
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2033
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 11, 2026 · Synced Sep 8, 2026, 3:06 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Nilotinib and Imatinib Mesylate After Donor Stem Cell Transplant in Treating Patients With ALL or CML

NCT00702403
View directory record Official record
Conditions
Accelerated Phase Chronic Myelogenous Leukemia, Adult Acute Lymphoblastic Leukemia in Remission, Blastic Phase Chronic Myelogenous Leukemia, Childhood Acute Lymphoblastic Leukemia in Remission, Childhood Chronic Myelogenous Leukemia, Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Chronic Phase Chronic Myelogenous Leukemia, Philadelphia Positive Adult Acute Lymphoblastic Leukemia, Philadelphia Positive Childhood Acute Lymphoblastic Leukemia, Recurrent Adult Acute Lymphoblastic Leukemia, Recurrent Childhood Acute Lymphoblastic Leukemia, Relapsing Chronic Myelogenous Leukemia, Untreated Adult Acute Lymphoblastic Leukemia, Untreated Childhood Acute Lymphoblastic Leukemia
Interventions
nilotinib, imatinib mesylate, pharmacological study
Drug · Other
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
Not listed
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2013
U.S. locations
5
States / cities
Stanford, California • Tampa, Florida • Portland, Oregon + 1 more
Source: ClinicalTrials.gov public record
Updated Aug 9, 2017 · Synced Sep 8, 2026, 3:06 AM EDT